| Open Document File Size: 1,40 MBShare Result on Facebook
City Montreal / / Company AEs / Tablet Therapeutic Class Anti-Hepatitis B (Nucleotide Analog) Applicant Gilead Sciences Inc. / CHB / Gilead Sciences / Tablet Pharmaceuticals / HBV / / Continent Africa / / Country United States / United Kingdom / / Event FDA Phase / / Facility Laboratory Findings / / IndustryTerm Food effect / treatment of hepatitis B / food / / MedicalCondition proteinuria / abdominal pain / disease / headache / HBV / nasopharyngitis / Hepatocellular carcinoma / hematuria / nausea / cirrhosis / glycosuria / Hepatitis B / diarrhea / membranous glomerulonephritis / infection / increased ALT / hepatitis / renal failure / cough / inflammation / infections / hepatic decompensation / pharyngitis / chronic hepatitis B / syndrome / Inflammatory / fibrosis / upper respiratory tract infection / / MedicalTreatment antiviral therapy / / Person Charlene Brown / Review Yodit Belew / Yodit Belew / / Position EXECUTIVE / / Product Formulation Tablet / Tyzeka / GS / Pegasys / Hepsera / lamivudine / adenosine / Intron A / Baraclude / Epivir-HBV / B / Intron A® / HBeAg / Hepsera® (adefovir dipivoxil) Tablet / United States / Hepsera® tablet / SE5-011 / formulation / / Region Far East / / Technology alpha / PHARMACOKINETICS / PHARMACODYNAMICS / /
SocialTag |